Biogen Exploring Tecfidera Safety Perceptions As Sales Slowdown Continues
This article was originally published in The Pink Sheet Daily
Slowing sales growth continues for Biogen’s Tecfidera in the first quarter, due in part to lingering questions regarding safety. In an April 24 earnings call, the company also provided an update on Phase III study plans for its Alzheimer’s candidate, aducanumab.
You may also be interested in...
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
Insulin Prices, Cancer Treatment Innovation Pushed In State Of The Union As Biden Faces Divided Congress
Expanded federal research efforts around cancer treatment was one of a handful of bipartisan goals that President Biden highlighted in his State of the Union address.
Regulatory attorneys suggest different issues that might form the basis of manufacturer-sponsored litigation against the Centers for Medicare and Medicaid Services.